Are psychedelic drug treatments seeing a comeback in psychiatry?
Progress in Neurology and Psychiatry October 1, 2008 DOI: 10.1002/pnp.94
Summary
AI-generated from the abstractAfter a nearly 40-year pause, psychedelic drugs are being studied again as possible aids to psychotherapy for treatment-resistant anxiety disorders and addictions. This research presents a promising future for these substances, whose reputation suffered due to recreational use since the 1960s. Through careful, evidence-based studies, these medications may return to their original role as valid and effective tools in clinical medicine and neuroscience.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Psychedelic drugs are being researched as possible adjuncts to psychotherapy for treatment-resistant anxiety disorders and addictions. |
Abstract
AbstractAfter a hiatus of nearly 40 years, psychedelic drugs (or hallucinogens) are being increasingly researched as possible adjuncts to psychotherapy for treatment‐resistant anxiety disorders and addictions.This research offers an exciting future for this class of drugs whose image has been tarnished by recreational use since the 1960s.Through cautious and evidence‐based studies, these medications could be finding their way back to where they began their lives: as valid and effective tools for clinical medicine and neuroscientific research. Copyright © 2008 Wiley Interface Ltd